Royal Marsden Hospital
Head of radioisotope physics
Dr Glenn Flux is Head of Radioisotope Physics at the Royal Marsden Hospital and Institute of Cancer Research in Sutton, UK. His main research focus is on translational quantitative SPECT and PET imaging and its application to internal dosimetry for molecular radiotherapy. He has been involved in the development of imaging and dosimetry for clinical procedures including I-131 mIBG treatment of neuroblastoma and the treatment and palliation of bone metastases from prostate cancer with Re-186 HEDP and Ra-223. He has published over 100 peer reviewed articles and received research funding from national and international bodies. He is a founder member of the EANM Dosimetry Committee and is currently chair of the British Nuclear Medicine Society Molecular Radiotherapy committee.
The emergence and resurgence of radiotherapeutics for cancer treatment
Cancer treatment with radiopharmaceuticals is growing rapidly with many new radiotherapeutics either in development or early phase trials. Molecular radiotherapy and theragnostics promise to offer significant advances in cancer care and the market is expected to grow by 30% per annum for the foreseeable future. This presentation will review the potential impact of this expansion for industry, academia, and patient benefit.
EVEN MORE SEMINARS
Profess Liz Ward Centre for Functioning and Health Research, Metro South Hospital and Health Service, and The Univers
Laryngectomy rehabilitation: Opportunities for improving speech pathology supports via telehealth
Laura Allington University College London Hospitals NHS Foundation Trust
Operational challenges of planning a new NHS high energy proton service.
Merina Ahmed Royal Marsden NHS foundation Trust
Stereotactic Radiotherapy for lung tumours and oligometastatic disease
Nirmesh Patel Cambridge Cancer Genomics
Monitoring cancer evolution through smart genomics and liquid biopsies
Imran Liaquat MBChB BSc MedSci MRCS FRCS MEd NHS Lothian, Scotland
Optimising Surgical Resection in Low Grade Glioma Patients